Anavex Life Sciences Corp. (AVXL) Financial Statements
Industry: Biological Products, (No Diagnostic Substances)
In fiscal 2025, Anavex Life Sciences reported revenue of $0. Net income was -$46.4M, or -$0.54 per diluted share. Operating activities generated -$39.0M of cash. At fiscal year end, Anavex Life Sciences held $103.8M in total assets against $8.9M in total liabilities, including $102.6M of cash and equivalents.
Open the full interactive Anavex Life Sciences financials → Quarterly statements, key ratios, valuation history and price charts.
Anavex Life Sciences Key Stats
| Share Price | $1.48 |
|---|---|
| Market Cap | $137.5M |
| 52-Week Range | $1.48 – $9.36 |
| Shares Outstanding | 92.7 million (basic, 2026 Q3) |
Anavex Life Sciences Income Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 |
| Operating Income | — | — | -$51.0M | -$55.8M | -$52.9M | -$51.4M |
| Pre-Tax Income | -$26.3M | -$37.6M | -$47.6M | -$47.5M | -$43.0M | -$46.4M |
| Income Tax | $22,664 | $267,565 | $358,492 | $7,000 | — | — |
| Net Income | -$26.3M | -$37.9M | -$48.0M | -$47.5M | -$43.0M | -$46.4M |
| Diluted EPS | -$0.45 | -$0.54 | — | -$0.60 | -$0.52 | -$0.54 |
Anavex Life Sciences Quarterly Results
| 2025 Q4 | 2026 Q1 | 2026 Q2 | 2026 Q3 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Net Income | -$9.8M | -$5.7M | -$5.3M | $7.8M |
| Diluted EPS | -$0.12 | -$0.06 | -$0.06 | $0.08 |
Anavex Life Sciences Balance Sheet
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $29.2M | $152.1M | $149.2M | $151.0M | $132.2M | $102.6M |
| Total Assets | $34.5M | $161.6M | $152.7M | $154.4M | $135.6M | $103.8M |
| Total Liabilities | $7.3M | $10.8M | $10.2M | $12.5M | $15.3M | $8.9M |
| Shareholders' Equity | $27.2M | $150.8M | $142.5M | $141.9M | $120.3M | $94.9M |
Anavex Life Sciences Cash Flow Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash From Operations | -$21.3M | -$30.4M | -$24.2M | -$27.8M | -$30.8M | -$39.0M |
| Cash From Financing | $28.4M | $153.2M | $21.3M | $29.7M | $12.0M | $9.4M |
Figures from Anavex Life Sciences' 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full Anavex Life Sciences financials page for every line item.
Anavex Life Sciences Company Profile
| Ticker | AVXL |
|---|---|
| Exchange | Nasdaq |
| Industry | Biological Products, (No Diagnostic Substances) |
| Headquarters | New York, New York |
| Fiscal Year End | September 30 |
| SEC Filer Category | Large accelerated filer, smaller reporting company |
| SEC CIK | 0001314052 |
Frequently Asked Questions
What was Anavex Life Sciences' revenue in fiscal 2025?
Anavex Life Sciences (AVXL) reported revenue of $0 for fiscal 2025.
What is Anavex Life Sciences' annual revenue history?
Anavex Life Sciences' annual revenue by fiscal year: 2020: $0; 2021: $0; 2022: $0; 2023: $0; 2024: $0; 2025: $0.
What was Anavex Life Sciences' net income in fiscal 2025?
Anavex Life Sciences reported net income of -$46.4M for fiscal 2025.
What was Anavex Life Sciences' earnings per share (EPS) in fiscal 2025?
Anavex Life Sciences' diluted EPS was -$0.54 for fiscal 2025 (adjusted for any later stock splits).
What was Anavex Life Sciences' revenue last quarter?
In its most recent reported quarter (2026 Q3), Anavex Life Sciences reported revenue of $0.
How many shares of Anavex Life Sciences are outstanding?
Anavex Life Sciences reported a weighted average of 92.7 million basic shares outstanding in 2026 Q3.
What is Anavex Life Sciences' market cap?
Based on its latest closing price, Anavex Life Sciences (AVXL) has a market capitalization of about $137.5M.
When does Anavex Life Sciences' fiscal year end?
Anavex Life Sciences' fiscal year end, as registered with the SEC, is September 30.
Where is Anavex Life Sciences headquartered?
Anavex Life Sciences lists its business address in New York, New York in its SEC filings.
Anavex Life Sciences Competitors & Similar Companies
See all 136 Biological Products, (No Diagnostic Substances) companies →